What is the relevance of bioinformatics to pharmacology?

Trends in Pharmacological Sciences

Volumn 24, Issue 8, 2003, Pages 434-439

  Whittaker, Paul A ^a  

^a Novartis Institutes for Biomedical Research   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ANTIVIRUS AGENT; BIOLOGICAL MARKER; VACCINE;

BIOINFORMATICS; COMPUTER MODEL; DRUG INDUSTRY; GENETICS; GENOME ANALYSIS; GENOMICS; HUMAN; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; TOXICOGENOMICS; TRANSCRIPTOMICS;

EID: 0042160230     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(03)00197-4     Document Type: Review

References (75)

1. Dayhoff M.O. Computer analysis of protein evolution. Sci. Am. 221:1969;86-95.
2. Rybak B. A program for teaching bio-informatics. Bioscience Communications. 4:1978;158-159.
3. Baxevanis A.D. The Molecular Biology Database Collection: 2003 update. Nucleic Acids Res. 31:2003;1-12.
4. Luscombe N.M., et al. What is bioinformatics? A proposed definition and overview of the field. Methods Inf. Med. 40:2001;346-358.
5. Westhead D.R., Parish J.H. Bioinformatics. 2002;BIOS Scientific Publishers.
6. Scheel J., et al. Yellow pages to the transcriptome. Pharmacogenomics. 3:2002;791-807.
7. Slonim D.K. From patterns to pathways: gene expression data analysis comes of age. Nat. Genet. 32:2002;502-508.
8. Marshall T., Williams K.M. Proteomics and its impact upon biomedical science. Br. J. Biomed. Sci. 59:2002;47-64.
9. Weinstein J.N. 'Omic' and hypothesis-driven research in the molecular pharmacology of cancer. Curr. Opin. Pharmacol. 2:2002;361-365.
10. Broder S., Venter J.C. Sequencing the entire genomes of free-living organisms: the foundation of pharmacology in the new millennium. Annu. Rev. Pharmacol. Toxicol. 40:2000;97-132.
11. Orengo C.A., et al. Bioinformatics: Genes, Proteins and Computers. 2003;BIOS Scientific Publishers.
12. Zambrowicz B.P., Sands A.T. Knockouts model the 100 best-selling drugs - will they model the next 100? Nat. Rev. Drug Discov. 2:2003;38-51.
13. Corbin J.D., et al. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology. 60:2002;4-11.
14. Druker B.J. Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy. Eur. J. Cancer. 38:2002;S70-S76.
15. Whittaker P.A. From symptomatic treatments to causative therapy? Curr. Opin. Chem. Biol. 5:2001;352-359.
16. Drews J. Drug discovery: a historical perspective. Science. 287:2000;1960-1964.
17. Foord S.M. Receptor classification: post genome. Curr. Opin. Pharmacol. 2:2002;561-566.
18. Southan C. A genomic perspective on human proteases. FEBS Lett. 498:2001;214-218.
19. Manning G., et al. The protein kinase complement of the human genome. Science. 298:2002;1912-1934.
20. Wise A., et al. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem. 278:2003;9869-9874.
21. Chalker A.F., Lunsford R.D. Rational identification of new antibacterial drug targets that are essential for viability using a genomics-based approach. Pharmacol. Ther. 95:2002;1-20.
22. Lahm A., et al. Hepatitis C virus proteins as targets for drug development: the role of bioinformatics and modelling. Curr. Drug Targets. 3:2002;281-296.
23. De Groot A.S., et al. Immuno-informatics: mining genomes for vaccine components. Immunol. Cell Biol. 80:2002;255-269.
24. Hoffman S.L., et al. Plasmodium, human and Anopheles genomics and malaria. Nature. 415:2002;702-709.
25. Yuan J., et al. Genome analysis with gene-indexing databases. Pharmacol. Ther. 91:2001;115-132.
26. Pires M.R., et al. Whole-body gene expression by data mining. Genomics. 72:2001;34-42.
27. De Young M.P., et al. Bioinformatics-based discovery of a novel factor with apparent specificity to colon cancer. In Vivo. 16:2002;239-248.
28. Wittenberger T., et al. An expressed sequence tag (EST) data mining strategy succeeding in the discovery of new G-protein coupled receptors. J. Mol. Biol. 307:2001;799-813.
29. Barrett J.C., Kawasaki E.S. Microarrays: the use of oligonucleotides and cDNA for the analysis of gene expression. Drug Discov. Today. 8:2003;134-141.
30. Henriksen P.A., Kotelevtsev Y. Application of gene expression profiling to cardiovascular disease. Cardiovasc. Res. 54:2002;16-24.
31. Shilling P.D., Kelsoe J.R. Functional genomics approaches to understanding brain disorders. Pharmacogenomics. 3:2002;31-45.
32. Butte A. The use and analysis of microarray data. Nat. Rev. Drug Discov. 1:2002;951-960.
33. Dewey T.G. From microarrays to networks: mining expression time series. Drug Discov. Today. 7:2002;S170-S175.
34. Whittaker P.A. Genes for asthma: much ado about nothing? Curr. Opin. Pharmacol. 3:2003;212-219.
35. Stein L. Genome annotation: from sequence to biology. Nat. Rev. Genet. 2:2001;493-503.
36. Thornton J.M. From genome to function. Science. 292:2001;2095-2097.
37. Tucker C.L., et al. Towards an understanding of complex protein networks. Trends Cell Biol. 11:2001;102-106.
38. Legrain P., et al. Protein-protein interaction maps: a lead towards cellular functions. Trends Genet. 17:2001;346-352.
39. Dahl S.G., et al. Bioinformatics: from genome to drug targets. Ann. Med. 34:2002;306-312.
40. Breinbauer R., et al. From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries. Angew. Chem. Int. Ed. Engl. 41:2002;2879-2890.
41. Hayes R.J., et al. Combining computational and experimental screening for rapid optimization of protein properties. Proc. Natl. Acad. Sci. U. S. A. 99:2002;15926-15931.
42. Blundell T.L., et al. High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discov. 1:2002;45-54.
43. Schuffenhauer A., et al. An ontology for pharmaceutical ligands and its application for in silico screening and library design. J. Chem. Inf. Comput. Sci. 42:2002;947-955.
44. Zheng X.F., Chan T.F. Chemical genomics: a systematic approach in biological research and drug discovery. Curr. Issues Mol. Biol. 4:2002;33-43.
45. Lesko L.J., Woodcock J. Pharmacogenomic-guided drug development: regulatory perspective. Pharmacogenomics J. 2:2002;20-24.
46. Petricoin E.F. III, et al. Medical applications of microarray technologies: a regulatory science perspective. Nat. Genet. 32:2002;474-479.
47. Altman R.B., Klein T.E. Challenges for biomedical informatics and pharmacogenomics. Annu. Rev. Pharmacol. Toxicol. 42:2002;113-133.
48. Fielden M.R., et al. In silico approaches to mechanistic and predictive toxicology: an introduction to bioinformatics for toxicologists. Crit. Rev. Toxicol. 32:2002;67-112.
49. Lesko L.J., Atkinson A.J. Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu. Rev. Pharmacol. Toxicol. 41:2001;347-366.
50. Funkhouser J. Reinventing pharma: the theranostic revolution. Current Drug Discovery. 2002;17-19. ( http://www.currentdrugdiscovery.com/2002/august.html ).
51. Picard F.J., Bergeron M.G. Rapid molecular theranostics in infectious diseases. Drug Discov. Today. 7:2002;1092-1101.
52. Nicolette C.A., Miller G.A. The identification of clinically relevant markers and therapeutic targets. Drug Discov. Today. 8:2003;31-38.
53. Yeatman T.J. The future of clinical cancer management: one tumor, one chip. Am. Surg. 69:2003;41-44.
54. Petricoin E.F., et al. Clinical proteomics: translating benchside promise into bedside reality. Nat. Rev. Drug Discov. 1:2002;683-695.
55. Srinivas P.R., et al. Proteomics for cancer biomarker discovery. Clin. Chem. 48:2002;1160-1169.
56. Pirmohamed M., Park B.K. Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci. 22:2001;298-305.
57. Pickar D., Rubinow K. Pharmacogenomics of psychiatric disorders. Trends Pharmacol. Sci. 22:2001;75-83.
58. Schmidt B., et al. Genotypic drug resistance interpretation systems-the cutting edge of antiretroviral therapy. AIDS Rev. 4:2002;148-156.
59. Blower P.E., et al. Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data. Pharmacogenomics J. 2:2002;259-271.
60. Emerson L.R., et al. Relationship between chloroquine toxicity and iron acquisition in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 46:2002;787-796.
61. Rockey W.M., Elcock A.H. Progress toward virtual screening for drug side effects. Proteins. 48:2002;664-671.
62. Amin R.P., et al. Genomic interrogation of mechanism(s) underlying cellular responses to toxicants. Toxicology. 181-182:2002;555-563.
63. Ulrich R., Friend S.H. Toxicogenomics and drug discovery: will new technologies help us produce better drugs? Nat. Rev. Drug Discov. 1:2002;84-88.
64. Kennedy S. The role of proteomics in toxicology: identification of biomarkers of toxicity by protein expression analysis. Biomarkers. 7:2002;269-290.
65. Hamadeh H.K., et al. Discovery in toxicology: mediation by gene expression array technology. J. Biochem. Mol. Toxicol. 15:2001;231-242.
66. Rushmore T.H., Kong A.N. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr. Drug Metab. 3:2002;481-490.
67. Nicholson J.K., et al. Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 1:2002;153-161.
68. Aardema M.J., MacGregor J.T. Toxicology and genetic toxicology in the new era of 'toxicogenomics': impact of '-omics' technologies. Mutat. Res. 499:2002;13-25.
69. Lindon J.C., et al. Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol. Appl. Pharmacol. 187:2003;137-146.
70. Kitano H. Computational systems biology. Nature. 420:2002;206-210.
71. Gilman A.G., et al. Overview of the Alliance for Cellular Signaling. Nature. 420:2002;703-706.
72. Li J., et al. The Molecule Pages database. Nature. 420:2002;716-717.
73. Kloos D.U., et al. The TGF-beta-Smad network: introducing bioinformatic tools. Trends Genet. 18:2002;96-103.
74. Noble D. The future: putting Humpty-Dumpty together again. Biochem. Soc. Trans. 31:2003;156-158.
75. Grass G.M., Sinko P.J. Physiologically-based pharmacokinetic simulation modelling. Adv. Drug Deliv. Rev. 54:2002;433-451.